Clinical data published in Clinical Microbiology and Infection support use of MeMed’s test in reducing antibiotic overuse in children The…
New Trial Designed to Further Investigate the Immune-Based MOA of Trilaciclib and Help Determine Future Target Tumor Types and Treatment…
PDUFA date extended by three months to April 5, 2022 No Additional Data Requested Following Meeting with FDA NEW HAVEN,…
Surface to receive $30 million milestone payment upon first patient treated in the Phase 1 studyCAMBRIDGE, Mass., Dec. 01, 2021…
CNM-Au8 has favorable impact on progression of ALS as measured by joint rank comparison of combined survival and ALSFRS-R change…
Vancouver, B.C, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Origin Therapeutics Holdings Inc. (the “Company” or “Origin Therapeutics”) an actively managed…
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated…
Philips ClarifEye AR at Armed Forces Hospital Oman Philips ClarifEye AR at Sant Joan de Déu Barcelona Children's Hospital Spain…
MIAMI, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing…
Company announcement no. 24 - 211 December 2021 NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA. THE…